Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | MMP3 | P08254 | 5/20 | 0.40 |
| ▸ | MMP8 | P22894 | 4/20 | 0.40 |
| ▸ | MMP1 | P03956 | 4/20 | 0.40 |
| ▸ | MMP9 | P14780 | 3/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | GBA1 | P04062 | 2/20 | 0.37 |
| ▸ | UGCG | Q16739 | 2/20 | 0.37 |
| ▸ | GBA2 | Q9HCG7 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27089882 | 0.95 | L3MBTL1 (0.40) | L3MBTL1TDP1MMP3MMP8MMP1 | |
| SCHEMBL22406078 | 0.90 | PLA2G10 (0.38) | L3MBTL1TDP1MMP3MMP8MMP1 | |
| SCHEMBL15516517 | 0.86 | L3MBTL1 (0.41) | L3MBTL1TDP1MMP3MMP8MMP1 | |
| SCHEMBL15516518 | 0.86 | L3MBTL1 (0.41) | L3MBTL1TDP1MMP3MMP8MMP1 | |
| SCHEMBL18413379 | 0.79 | PLA2G10 (0.36) | L3MBTL1TDP1MMP3MMP8MMP1 | |
| SCHEMBL13986786 | 0.79 | L3MBTL1 (0.39) | L3MBTL1TDP1MMP3MMP8MMP1 | |
| SCHEMBL7218954 | 0.79 | CA1 (0.38) | TSHRKMT2A | |
| SCHEMBL20581987 | 0.79 | TSHR (0.40) | L3MBTL1TDP1MMP3MMP8MMP1 | |
| SCHEMBL20581985 | 0.79 | TSHR (0.40) | L3MBTL1TDP1MMP3MMP8MMP1 | |
| SCHEMBL2560206 | 0.79 | L3MBTL1 (0.47) | L3MBTL1TDP1HRH4HRH3GBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4674856-A2 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | Alnylam Pharmaceuticals, Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| EP-2788006-B1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | ALNYLAM PHARMACEUTICALS INC (US) | 2026-01-07 | — | — | EP | disclosed |
| EP-3254672-B1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | ALNYLAM PHARMACEUTICALS INC (US) | 2025-08-20 | — | — | EP | disclosed |
| US-12364762-B2 | Biodegradable lipids for the delivery of active agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2025-07-22 | — | — | US | disclosed |
| US-12350338-B2 | Biodegradable lipids for the delivery of active agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2025-07-08 | — | — | US | disclosed |
| US-12343398-B2 | Biodegradable lipids for the delivery of active agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2025-07-01 | — | — | US | disclosed |
| US-12239709-B2 | Biodegradable lipids for the delivery of active agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2025-03-04 | — | — | US | disclosed |
| EP-4481047-A2 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | Alnylam Pharmaceuticals, Inc. (US) | 2024-12-25 | — | — | EP | disclosed |
| US-20240398956-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | BANK OF AMERICA, N.A. | 2024-12-05 | — | — | US | disclosed |
| US-20240285767-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | BANK OF AMERICA, N.A. | 2024-08-29 | — | — | US | disclosed |
| US-9682922-B2 | Biodegradable lipids for the delivery of active agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| EP-2575764-B1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | ALNYLAM PHARMACEUTICALS INC (US) | 2017-04-19 | — | — | EP | disclosed |
| US-20160009637-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | BANK OF AMERICA, N.A. | 2016-01-14 | — | — | US | disclosed |
| US-20150273068-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | BANK OF AMERICA, N.A. | 2015-10-01 | — | — | US | disclosed |
| US-9061063-B2 | Biodegradable lipids for the delivery of active agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-06-23 | — | — | US | disclosed |
| US-9012498-B2 | Biodegradable lipids for the delivery of active agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-04-21 | — | — | US | disclosed |
| EP-2788006-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | Alnylam Pharmaceuticals, Inc. (US) | 2014-10-15 | — | — | EP | disclosed |
| US-20130195920-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-08-01 | — | — | US | disclosed |
| WO-2013086354-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-06-13 | — | — | WO | disclosed |
| US-20120027803-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120027803-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | LIPA, CETP, APOB | L3MBTL1 1399/4885TDP1 1576/4885MMP3 1002/4885 |
| US-20160009637-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | LIPA, CETP, APOB | L3MBTL1 1399/4885TDP1 1576/4885MMP3 1002/4885 |
| US-12343398-B2 | Biodegradable lipids for the delivery of active agents | LIPA, APOB, CETP | L3MBTL1 1228/4885TDP1 1779/4885MMP3 1063/4885 |
| US-20240398956-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | LIPA, APOB, CETP | L3MBTL1 1228/4885TDP1 1779/4885MMP3 1063/4885 |
| US-12350338-B2 | Biodegradable lipids for the delivery of active agents | LIPA, APOB, CETP | L3MBTL1 1228/4885TDP1 1779/4885MMP3 1063/4885 |
| US-20130195920-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | LIPA, APOB, CETP | L3MBTL1 1228/4885TDP1 1779/4885MMP3 1063/4885 |
| US-20150273068-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | LIPA, APOB, CETP | L3MBTL1 1228/4885TDP1 1779/4885MMP3 1063/4885 |
| US-20240285767-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | LIPA, APOB, CETP | L3MBTL1 1228/4885TDP1 1779/4885MMP3 1063/4885 |
| US-12239709-B2 | Biodegradable lipids for the delivery of active agents | LIPA, APOB, CETP | L3MBTL1 1228/4885TDP1 1779/4885MMP3 1063/4885 |
| US-12364762-B2 | Biodegradable lipids for the delivery of active agents | LIPA, APOB, CETP | L3MBTL1 1228/4885TDP1 1779/4885MMP3 1063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.